#United States #San Diego #Class Action #Securities Fraud #ADMA Biologics

Important Class Action Lawsuit Alert for ADMA Biologics Investors

ADMA Biologics, Inc., a company actively involved in developing plasma-derived biologics, is currently facing a significant legal challenge. Investors who suffered considerable losses while purchasing ADMA shares from August 9, 2024, to March 25, 2026, now have a crucial opportunity to step forward as lead plaintiffs in a class action lawsuit against the company. This opportunity must be seized before the deadline on August 10, 2026.

Background

The law firm Robbins Geller Rudman & Dowd LLP has taken the lead in notifying potential plaintiffs about this class action lawsuit, officially titled Mazzarino v. ADMA Biologics, Inc., No. 26-cv-06918 (D.N.J.). The lawsuit asserts that ADMA Biologics and its executive officers have violated the Securities Exchange Act of 1934 by providing investors with misrepresented information and failing to disclose critical details about the company’s operations.

Allegations Against ADMA Biologics

Our coverage delves into serious allegations against ADMA. Among the key concerns highlighted are:
1. Undisclosed Related Party Transactions: The lawsuit claims that ADMA engaged in transactions with related parties that were not disclosed to investors, potentially affecting financial transparency.
2. Channel Stuffing Concerns: The company allegedly used questionable practices, termed channel stuffing, which adjusts revenue reports to create a misleading picture of financial health.
3. Inadequate Internal Controls: It is accused of not having sufficient internal controls in place, raising questions about the reliability of its financial statements.

The impetus of the lawsuit stems from a report issued by Culper Research on March 24, 2026. This critical report suggested that ADMA’s reported growth was primarily due to manipulative practices, indicating that without revenue adjustments, the company would have faced an actual decline of 3% in 2025, contrary to positive figures previously advertised.

Following these revelations, ADMA’s stock price saw significant declines; reports indicated a drop of over 16% as investors reacted to the abrupt negative news.

Lead Plaintiff Process

With the passage of the Private Securities Litigation Reform Act of 1995, investors who lost money during the class period are eligible to act as lead plaintiffs in the ongoing lawsuit. A lead plaintiff typically holds the most substantial financial interest in the case and plays an essential role in directing the proceedings. Notably, you don’t need to be the lead plaintiff to recover losses, but this position allows for greater influence over legal decisions and represents the class's interests.

If you believe you fit the criteria, it is advised to contact Robbins Geller at 800-851-7783 or through email at email protected] to initiate your involvement in the lawsuit. Further information can be found on their [official page.

Conclusion

The urgency for ADMA Biologics investors cannot be understated. As the deadline approaches, potential plaintiffs must gather their documentation and act swiftly to ensure that their voices are heard in court. This lawsuit is not only a chance for recourse but also an opportunity to hold companies accountable for their actions and promote a fair financial environment.

If you are among those who sustained losses, consider reaching out to Robbins Geller and participating in this class action lawsuit. Make your presence known now to contribute towards justice and potentially recover financial losses incurred by misleading corporate actions.